How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Therapeutic Stent Market
- By Stent Type: Bare Metal Stents (BMS), Drug-Eluting Stents (DES), Bioabsorbable Stents, Covered Stents, Dual Therapy Stents
- By Material: Cobalt-Chromium, Stainless Steel, Platinum-Chromium, Polymer-based, Magnesium Alloy
- By Application: Coronary Artery Disease, Peripheral Artery Disease, Neurovascular Stenting, Ureteral Stenting, Biliary Stenting
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
- By Procedure Type: Percutaneous Coronary Intervention (PCI), Peripheral Angioplasty, Neurovascular Intervention
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Bare Metal Stents (BMS) leads By Stent Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Therapeutic Stent Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Stent Type 5
Material 5
Application 5
End User 3
Procedure Type 3
Companies profiled
Abbott Laboratories
Boston Scientific Corporation
Medtronic plc
Terumo Corporation
BIOTRONIK SE & Co. KG
C.R. Bard
Inc. (now part of BD)
Cook Medical
B. Braun Melsungen AG
Sino Medical Sciences Technology Inc.
MicroPort Scientific Corporation
Lepu Medical Technology (Beijing) Co. Ltd.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →BIOTRONIK SE & Co. KG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →C.R. Bard
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Inc. (now part of BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Cook Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →B. Braun Melsungen AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sino Medical Sciences Technology Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →MicroPort Scientific Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Lepu Medical Technology (Beijing) Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →OrbusNeich Medical Group Holdings Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →LivaNova PLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cardinal Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Johnson & Johnson (Cordis division)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →
Global · 2025–2033
$5,760M by 2033 · 5.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Bare Metal Stents (BMS)50.6
- Drug-Eluting Stents (DES)12.0
- Bioabsorbable Stents14.3
- Covered Stents8.0
- Dual Therapy Stents15.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,223M → $2,008M · 6.4%
Europe$852.7M → $1,238M · 4.8%
Asia Pacific$778.6M → $1,129M · 4.8%
Latin America$482.0M → $829.8M · 7.0%
Middle East and Africa$370.8M → $580.0M · 5.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.612026
5.632027
5.642028
5.662029
5.662030
5.672031
5.692032
5.692033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories22.5
- Boston Scientific Corporation23.6
- Medtronic plc8.0
- Terumo Corporation5.2
- BIOTRONIK SE & Co. KG6.8
- C.R. Bard5.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Stent Type13.9%
Material28.6%
Application15.9%
End User21.1%
Procedure Type20.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe21.4
- Asia Pacific19.5
- Latin America14.3
- Middle East and Africa10.0
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 73 | 99 | 88 | 99 | 92 | 95 | 91 |
| Boston Scientific Corporation | 89 | 76 | 73 | 71 | 84 | 84 | 80 |
| Medtronic plc | 67 | 86 | 86 | 79 | 73 | 81 | 79 |
| Terumo Corporation | 65 | 78 | 69 | 82 | 62 | 63 | 70 |
| BIOTRONIK SE & Co. KG | 55 | 58 | 76 | 60 | 74 | 59 | 64 |
| C.R. Bard | 63 | 69 | 57 | 67 | 56 | 56 | 61 |
| Inc. (now part of BD) | 41 | 59 | 62 | 57 | 42 | 57 | 53 |
| Cook Medical | 35 | 59 | 60 | 53 | 58 | 56 | 54 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Boston Scientific Corporation | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Medtronic plc | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Terumo Corporation | ◐ | ✓ | − | ◐ | ✓ | − |
| BIOTRONIK SE & Co. KG | − | ◐ | ◐ | − | ✓ | − |
| C.R. Bard | − | ◐ | − | ◐ | − | ◐ |
| Inc. (now part of BD) | − | ◐ | − | − | − | ◐ |
| Cook Medical | − | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories91
2Boston Scientific Corporation80
3Medtronic plc79
4Terumo Corporation70
5BIOTRONIK SE & Co. KG64
6C.R. Bard61
7Cook Medical54
8Inc. (now part of BD)53
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Abbott LaboratoriesBoston Scientific CorporationMedtronic plc
Challenger1
Strong scale, closing on the leaders.
Terumo Corporation
Contender2
Focused players with pockets of strength.
BIOTRONIK SE & Co. KGC.R. Bard
Niche2
Specialists in a single segment or region.
Inc. (now part of BD)Cook Medical
Go-to-market strategy
Land Stent Type in North America, then scale across Therapeutic Stent Market — a $68M beachhead inside a $1.10B market.
Beachhead (SOM)$68Mobtainable near-term
Serviceable (SAM)$410Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Bare Metal Stents (BMS)
Best fit — highest urgency & budget in Stent Type.
Economic buyer76 fit
Drug-Eluting Stents (DES)
Strong fit — clear ROI and a fast path to value.
End user64 fit
Bioabsorbable Stents
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Stent Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Stent Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Therapeutic Stent Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified25%
Evaluation11%
Closed-won7%
$10.5KCAC
$51KLTV
4.9:1LTV : CAC
< 4 moCAC payback
Investment thesis
Therapeutic Stent Market is a resilient opportunity — $2.68B by 2033, compounding at 3.6%.
TAM · 2025$2.01Btoday
TAM · 2033$2.68Bforecast
CAGR3.6%2027–2033
Cumulative$21.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.68BTotal addressable market
SAM$1.06BServiceable available market
SOM$203MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.6% CAGR
Demand compounds through 2033, outpacing GDP across Stent Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Stent Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.68BLarge & growingTAM by 2033 at 3.6% CAGR
$1.06BServiceable nowreachable with today’s model
$203MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.09BBear2.4% CAGR
$2.68BBase3.6% CAGR
$3.42BBull4.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Therapeutic Stent Market — a $7.10B market by 2033. Plan: grow share from 6.9% to 13.1%.
Market size · 2033$7.10Btotal addressable
Market CAGR3.4%2027–2033
Target share13.1%from 6.9% today
Revenue ambition$930Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 13.1% | Behind |
| Revenue | $533M | $930M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.3% | 45.3% | On track |
| Customer retention | 90.7% | 93.6% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Stent Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Material capability
A defensible second engine — invest in Material to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Stent Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $120M capacity & capability investment
- Greenlight bolt-on M&A in Material
- Authorise North America expansion plan
- Fund R&D program for Stent Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Sales deck · value proposition
Win the Therapeutic Stent Market conversation — a $4.08B market you can size, segment and defend in minutes.
Market size · 2033$4.08Btotal opportunity
Growth5.8%CAGR to 2033
Addressable buyers1,187+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Stent Type
Goal Grow share in Stent Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 3 mopayback period
$73K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Abbott LaboratoriesBoston Scientific CorporationMedtronic plcTerumo CorporationBIOTRONIK SE & Co. KGC.R. BardInc. (now part of BD)Cook Medical+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Therapeutic Stent Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Therapeutic Stent Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Medical Suction Devices Market
Market size, share, segmentation and regional forecast.
$2.9B by 2032 · 10.56% CAGR
View reportPolio Vaccines Market
Market size, share, segmentation and regional forecast.
$3.1B by 2032 · 6.38% CAGR
View reportPreventive Vaccine Market
Market size, share, segmentation and regional forecast.
$11.5B by 2031 · 5.05% CAGR
View reportOperating Room Equipments Market
Market size, share, segmentation and regional forecast.
$9.0B by 2032 · 4.87% CAGR
View reportOxygen Conserver Device Market
Market size, share, segmentation and regional forecast.
$11.4B by 2031 · 5.20% CAGR
View reportOxygen Therapy Equipments Market
Market size, share, segmentation and regional forecast.
$13.9B by 2033 · 3.83% CAGR
View reportPill Organiser Market
Market size, share, segmentation and regional forecast.
$5.7B by 2032 · 5.38% CAGR
View reportClostridium Vaccine Market
Market size, share, segmentation and regional forecast.
$8.6B by 2031 · 10.05% CAGR
View reportTissue Forcep Market
Market size, share, segmentation and regional forecast.
$10.2B by 2033 · 4.72% CAGR
View reportAlumina Substrate for Chip Resistor Market
Market size, share, segmentation and regional forecast.
$5.3B by 2033 · 7.30% CAGR
View reportOtoscopes Market
Market size, share, segmentation and regional forecast.
$5.8B by 2033 · 4.46% CAGR
View reportRespiratory Drug Market
Market size, share, segmentation and regional forecast.
$795M by 2032 · 7.18% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.